Unoje, O, Hussain, Y, Habib, A, Claeys, K, Gwathmey, K, Sahagian, G, Cortés-Vicente, E, Liu, L, Jimenez, R, Patel, M, Masschaele, D, Mantegazza, R, Meisel, A, Seth, A, Attarian, S. Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. ANNALS OF NEUROLOGY. 2025; 98DOI:. PMID:. IF:7.700(Q1/1D).

Sánchez-Aced, E, Moya-Llamas, B, Escabias, JA, Torres, S, Colom-Cadena, M, Pegueroles, J, de Quintana-Schmidt, C, Bayes, A, Molina-Porcel, L, Aldecoa, I, Belbin, O, Fortea, J, Spires-Jones, T, Pujals, S, Sirisi, S, Lleo, A. Enhancing Lateral Resolution Using Two-Colour Direct Stochastic Optical Reconstruction Microscopy to Unravel Synaptic Tau Pathology in Alzheimer's Disease. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2025; 51(2)DOI:10.1111/nan.70010. PMID:40025904. IF:3.400(Q1/3D).

Martín-Aguilar, L, Querol, L. Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic". EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32(2)DOI:10.1111/ene.70069. PMID:39931912. IF:3.900(Q1/3D).

Neal, MA, Bolano-Diaz, CF, Richardson, M, Michell-Sodhi, J, Muni-Lofra, R, James, MK, Hollingsworth, KG, Hilsden, H, Wilson, I, Blamire, AM, Straub, V, Thelwall, PE, Diaz-Manera, J. Rapid Quantitative Assessment of Muscle Sodium Dynamics After Exercise Using 23Na-MRI in Dysferlinopathy and Healthy Controls. Journal of Cachexia Sarcopenia and Muscle. 2025; 16(1)DOI:10.1002/jcsm.13709. PMID:39900102. IF:9.100(Q1/1D).

Dominguez-González, C, Iannucci, D, Clark, J, Martin-Jiménez, P, Hold, S, Oliva, P, Bischinger, A, Gallardo, E, Diaz-Manera, J. Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease. NEUROMUSCULAR DISORDERS. 2026; 60DOI:10.1016/j.nmd.2026.106359. PMID:41638029. IF:2.800(Q2/5D).

Vesperinas, A, Rocaspana-Codana, J, Reyes-Leiva, D, Caballero-Avila, M, Carbayo, A, Collet-Vidiella, R, Llanso, L, Gallardo, E, Turon-Sans, J, Rojas-Garcia, R, Cortes-Vicente, E. Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic. NEUROMUSCULAR DISORDERS. 2026; 59DOI:10.1016/j.nmd.2025.106284. PMID:41442860. IF:2.800(Q2/5D).

Schirinzi, E, Bochicchio, MA, Lochmüller, H, Vissing, J, Jordie-Diaz-Manerae, Evangelista, T, Plançon, JP, Fanucci, L, Marini, M, Tonacci, A, Mancuso, M, Segovia-Kueny, S, Toscano, A, Angelini, C, Schoser, B, Sacconi, S, Siciliano, G, e-NMD Grp. E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021: Remote Monitoring: New Solutions for New Avenues in Neuromuscular Disorders. Journal Of Neuromuscular Diseases. 2026; 13(1)DOI:10.3233/JND-230091. PMID:38728200. IF:3.400(Q2/3D).

Allen, JA, Querol, L, Suresh, N, Remmerie, A, Mole, T, McCoy, K, Butler, L, van Hoorick, B, Kuwabara, S, van Doorn, PA, Lewis, RA. Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial. Therapeutic Advances in Neurological Disorders. 2026; 19DOI:10.1177/17562864251405202. PMID:41583073. IF:4.100(Q1/2D).

Armangué, T, Gómez-Ballesteros, R, Querol, L, Gutiérrez-Gutiérrez, G, Sotoca, J, Luque, AA, Villaverde, R, Reyes, V, Salas, E, Diaz, P, Maurino, J, Cortés-Vicente, E. ORGANIZATIONAL SUPPORT IN ADOPTING NEW TREATMENTS FOR GENERALIZED MYASTHENIA GRAVIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

Forcadell-Díez, L, Pérez, G, Fernández, A, Puig-Barrachina, V, Subirats, IG, Cortés, E, Moral, PD, Juárez, O. HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Cegarra, PL, Caballero-Avila, M, De Lorenzo, A, Lleixà, C, Collet-Vidiella, R, Martín-Aguilar, L, Pascual-Goñi, E, Querol, L. Absence of Anti-LGI4 Autoantibodies in a European Cohort of CIPD Patients. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Collet-Vidiella, R, Caballero-Avila, M, Llarch, P, Tejada-Illa, C, Pascual-Goñi, E, Martín-Aguilar, L, Lleixà, C, Vesperinas, A, Carbayo-Viejo, A, Llansó, L, Rojas, R, Querol, L. CIDP With Anti-GM1 IgM Antibodies: A Continuum With Multifocal Motor Neuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Illa, CT, Pegueroles, J, Claramunt-Molet, M, Pi-Cervera, A, Heras-Delgado, A, Gascón-Fontal, J, Idelsohn-Zielonka, S, Rico, M, Vidal, N, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Collet-Vidiella, R, Llarch, P, Llansó, L, Carbayo-Viejo, A, Vesperinas, A, Querol, L, Pascual-Goñi, E. Balance Assessment in Patients With Peripheral Neuropathies Using Digital Biomechanical Biomarkers. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Hourcade, S, Chow, T, Chen, Y, Levit, M, Hammond, TR, Kramer, ML, Ternes, N, Seluzhytsky, A, Alonso-Alonso, M, Atassi, N, Lewis, RA. Exploratory Biomarker Analyses in a Phase 2 Trial of Riliprubart for Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Pinter, GL, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, Van Doorn, PA, Lewis, RA. ADHERE plus Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and Efficacy of Riliprubart in CIDP: 76-Week Phase 2 Trial Results. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, Van de Walle, I, Persson, E, Vujcic, M, Van de Steen, O, Allen, J, Nobile-Orazio, E, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, WL. Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Hewamadduma, C, Peric, S, Claeys, K, Querol, L, Altamimi, S, Van de Walle, I, Persson, E, Van Hoomissen, I, Szmyd, G, Vujcic, M, Cadour, S, Van de Steen, O, Arvin-Berod, C, Allen, J. Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Falzone, Y, Sommer, C, Querol, L, Allen, J, Merkies, I, Van Doorn, P, Wallstroem, E, Lu, Y, Alonso-Alonso, M, Atassi, N, Lewis, RA. Riliprubart Phase 3 MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Stettner, M, Allen, J, Rinaldi, S, Pinter, GL, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Skripuletz, T, Lewis, R, Van Doorn, PA. Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive/Relapsing Active Disease: ADHERE Analysis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Wiegers, E, Steyerberg, E, Rajpar, A, Paliwal, P, Kanani, K, Kroon, HA, Dananberg, J, Cornblath, D, Willison, H, Kim, M, Gorson, K, Querol, L, Hartung, HP, Islam, Z, van Doorn, PA, Jacobs, B. Comparative Effectiveness In IGOS: ANX005 Versus Intravenous Immunoglobulin or Plasma Exchange For Guillain-Barre Syndrome. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Dymm, B, Van den Bergh, P, London, Z, Lewis, R, Querol, L, Harbo, T, Allen, J, Hadden, R, Van Doorn, PA. Development and Validation of a Digital Tool to Simplify Use of Guidelines For CIDP Diagnosis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Rajpar, A, Wiegers, E, Thomma, R, van Tilburg, S, Plomp, L, Sammelius, L, van Rijs, W, Harbo, T, Hartung, HP, Islam, Z, Lunn, M, Querol, L, Huizinga, R, Jacobs, B. Serum Neurofilament Light Chain in The International GBS Outcome Study: Predicting Disease Course and Outcome. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Peric, S, Cadour, S, Rigby, S, Van de Walle, I, Persson, E, Vujcic, M, Van de Steen, O, Mashchenko, O, Van Hoomissen, I, Allen, J, Katzberg, H, Kuwabara, S, Stettner, M, Rinaldi, S, van der Pol, WL. Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Lewis, R, Sommer, C, Bromberg, M, Barrera-Sierra, S, Arvin-Berod, C, Nisbet, P, Gelinas, D, Guptill, J, Wood, J. Management of Patients With Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

van der Pol, WL, Krijgsman, D, Querol, L, Persson, E, Rutjens, S, Cadour, S, Dijkxhoorn, K, Bloemenkamp, LM, de Zeeuw, E, Vujcic, M, Van de Walle, I. Empasiprubart in Multifocal Motor Neuropathy: Exploratory Analyses of the Phase 2 ARDA Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Eric, CT, Querol, L, Rodés, M, Thirugnanam, UN. Test Database and International Collaboration For Improving Peripheral Neurology in Resource Limited Settings. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Pinter, GL, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, van Doorn, P, Lewis, R. Impact of Prior Chronic Inflammatory Demyelinating Polyneuropathy Treatments in the ADHERE Trial: Post Hoc Analyses. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Vegezzi, E, Quartesan, I, Facchini, S, Curro, R, Mussinelli, R, Palladini, G, Milani, P, Nuvolone, M, Anan, I, Todorova, A, Tournev, I, Hegenbart, U, Schönland, S, Siepen, F, Gillmore, JD, Razvi, Y, Rowczenio, D, Coelho, T, Lemos, C, Alves-Ferreira, M, Mandich, P, Conceicao, I, Marques, W Jr, Tomaselli, P, Alves, G, Planté-Bordeneuve, V, Perrain, V, Hahn, K, Reilly, MM, Houlden, H, Pons, CC, Morales, M, Fabrizi, GM, Tagliapietra, M, Knoll, K, Trenkwalder, T, Cappelli, F, Argirò, A, Arregui, ALD, Agudo, PI, Torrón, RF, Arana-Achaga, X, Goena-Vives, C, Martinez, MLP, Aguirre, MA, Saez, M, Cisneros-Barroso, E, Luigetti, M, Berk, J, Prokaeva, T, Sekijima, Y, Yoshinaga, T, Garcia, SK, Théaudin, M, Guaraldi, P, Gragera, A, Rojas-García, R, Carbayo-Viejo, A, Gonzalez-Duarte, A, Cardenas-Soto, K, Menao, S, Kleopa, K, Zamba-Papanicolaou, E, Christodoulou, C, Waddington-Cruz, M, Foguel, D, Russo, M, Mazzeo, A, Sevilla, T, Sivera, R, Tasaki, M, Ueda, M, Reisin, R, Cejas, LL, Petit, C, Di Stefano, V, Antonini, G, Leonardi, L, Sanchez-Tejerina, D, Manganelli, F, Tozza, S, Pareyson, D, Fenu, S, Briani, C, Salvalaggio, A, Obici, L, Cortese, A. Genetic Modifiers in Hereditary and Wild-Type TTR Amyloidosis: Update on Genome-wide Association Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, van de Walle, I, Persson, E, Vujcic, M, van de Steen, O, Allen, J, Orazio, EN, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, W. Safety and efficacy data from the phase 2 ARDA study of empasiprubart in multifocal motor neuropathy. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and efficacy of riliprubart in chronic inflammatory demyelinating polyneuropathy: 76-week phase 2 trial results. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Rinaldi, S, Allen, J, Lin, J, Stettner, M, Merkies, I, Guptill, J, Hewamadduma, C, Istas, G, De Roeck, A, Kuwabara, S, Lauria, G, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Echaniz-Laguna, A, Van Hoorick, B, Yamasaki, R, Lewis, R, van Doorn, P. Effect of efgartigimod PH20 SC on lower limb function in chronic inflammatory demyelinating polyneuropathy in ADHERE. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Collet-Vidiella, R, Aguilar, LM, Lleix , C, Caballero-Avila, M, Illa, CT, Go i, EP, Llarch, P, Lluci -Carol, L, Tous, MS, Casasnovas, C, Guti rrez-Guti rrez, G, Fern ndez, JP, Carbayo, A, Gallardo, E, Vesperinas, A, Llanso, L, Fern ndez-Cadenas, I, Querol, L. Proteomic profiling of Guillain-Barre Syndrome using aptamers: Identifying and Validating Potential Biomarkers. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

De Lorenzo, A, Moretti, G, Bertini, A, Collet-Vidiella, R, Fasolino, A, Fortanier, E, Hadden, R, Islam, B, Kleopa, K, Cejas, LL, Leonardi, L, Mira, V, Peric, S, Rajabally, Y, Sevilla, T, Tomaselli, P, Tozza, S, Pisciotta, C, Pareyson, D, Nobile-Orazio, E, Doneddu, P. Chat-GPT-4o in diagnosis and management of real-life polyneuropathy cases: Comparative analysis with neurologists. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Hernandez, EM, Maqueda, JC, Fonseca, E, Marco, C, Chico, J, Fernandez, JG, Llaurado, A, Cabello, J, del Pino, L, Izquierdo, C, Cortes, E, G llego, J, Ros, M, Cald , R, Pelayo, A, Vizcaino, CS, Hernandez, H, Alvarez, J, Simo, M, Dalmau, J, Bruna, J, Velasco, R. Immune checkpoint inhibitor-related myositis-myasthenia: A retrospective cohort study in Spain. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Lewis, RA, Querol, L, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Lu, Y, Alonso, MA, Atassi, N, Hughes, AC. Efficacy of Riliprubart in chronic inflammatory demyelinating polyneuropathy: Phase 2 subgroup analyses. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Querol, L, Lewis, R, Sommer, C, Bromberg, M, Barrera-Sierra, S, Arvin-Berod, C, Nisbet, P, Gelinas, D, Guptill, J, Wood, J. Managing multifocal motor neuropathy: A survey of neurologists from Japan, Canada, and six European countries. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Reyes, V, Maurino, J, Armangu , T, Querol, L, Guti rrez-Guti rrez, G, Sotoca, J, Ares, A, Villaverde, R, Salas, E, D az-Abos, P, Cort s-Vicente, E, Gomez-Ballesteros, R, Ballesteros, J. Psychometric evaluation of resistance to change questionnaire: reluctance to adopt new treatments in myasthenia gravis. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Sacconi, S, Antozzi, C, Cortes-Vicente, E, Pascuzzi, R, Utsugisawa, K, Vissing, J, Vu, T, Bloemers, J, Grimson, F, Tarancon, T, Bril, V. Quality of life in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Skripuletz, T, Allen, J, Rinaldi, S, Lauria, G, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Stettner, M, Lewis, R, van Doorn, P. Efgartigimod in pretreated patients with CIDP and progressive/relapsing or persistent disease activity. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).